Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn't Make Any Money”
We recently published a list of Jim Cramer’s Thoughts on These 12 Stocks. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc. (ARWR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 11,111,111 | $141,555,554 | 2.21% | |
| 2. | Slate Path Capital David Greenspan | 5,232,000 | $66,655,680 | 1.2% | |
| 3. | Siren L.L.C. Raymond Debbane | 2,669,880 | $34,014,271 | -8% | 1.92% |
| 4. | Citadel Investment Group Ken Griffin | 986,951 | $12,573,756 | +169% | 0% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 723,800 | $9,221,212 | +69% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 500 | $11,000.00 | 36,080 | 2024-04-18 | Filing | |
| $25.00 | 500 | $12,500.00 | 35,580 | 2024-04-10 | Filing | |
| $27.34 | 150 | $4,101.00 | 35,080 | 2024-04-02 | Filing | |
| $27.50 | 850 | $23,375.00 | 34,930 | 2024-03-26 | Filing | |
| $28.00 | 400 | $11,200.00 | 34,080 | 2024-03-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.49 | 50,800 | $583,692.00 | 3,921,255 | 2025-04-11 | Filing | |
| $10.87 | 50,000 | $543,500.00 | 3,972,055 | 2025-04-10 | Filing | |
| $11.76 | 1,617 | $19,015.92 | 4,022,055 | 2025-04-09 | Filing | |
| $10.75 | 3,400 | $36,550.00 | 4,023,672 | 2025-04-09 | Filing | |
| $9.93 | 35,305 | $350,578.65 | 4,027,072 | 2025-04-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,926,154 | $253,859,202 | 0.01% | |
| 2. | 13,202,562 | $168,200,640 | 0% | |
| 3. | 6,999,249 | $89,170,432 | 0% | |
| 4. | 4,785,062 | $60,961,689 | 0.02% | |
| 5. | 3,315,082 | $42,234,145 | 0% |
News See All
Jim Cramer’s Thoughts on These 12 Stocks
On Tuesday’s episode of Mad Money, host Jim Cramer expressed concern over how President Donald Trump's actions have been impacting the stock market as he pointed out the confusion they create among ...
Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) therapeutic targeting adipose-specific gene expression to combat obesity.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrow Pharmaceuticals Conference Call. Throughout today’s recorded presentation, all participants will be in a listen-only mode.
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential
On April 24, Jill Carey Hall, BofA Securities head of U.S. small/mid-cap strategy, appeared on 'Closing Bell' to talk about the impact of tariffs on small caps.
12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript February 10, 2025Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Call Transcript November 26, 2024Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts
Potomac Wealth Advisors president Mark Avallone joined CNBC's 'The Exchange' on November 16 to discuss where he sees investing opportunities following Trump's election.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript August 8, 2024Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.